Overview

Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis

Status:
Recruiting

Trial end date:
2026-12-29

Target enrollment:

Participant gender:

Summary

The goal of this open label multicenter randomized controlled pragmatic superiority trial is to investigate the optimal treatment/tapering strategy with rituximab for patients with rheumatoid arthritis. The main questions it aims to answer are: - What is the optimal treatment/tapering strategy for rituximab in patients with rheumatoid arthritis in terms of reducing patient reported disease impact? - What is the optimal treatment/tapering strategy for rituximab in patients with rheumatoid arthritis in terms of therapeutic efficacy? Participants will be randomized to one of two study arms: - Tapering based on disease-activity guided dose reduction (experimental arm) - Tapering based on interval prolongation (active comparator arm)

Phase:

Phase 4

Details

Lead Sponsor:

Universitaire Ziekenhuizen KU Leuven

Collaborator:

Fonds voor Wetenschappelijk Reumaonderzoek (FWRO)

Treatments:

Rituximab